Cover Image
Market Research Report

Global Peptide Cancer Vaccine Market Research Report 2018

Published by QYResearch Product code 599426
Published Content info 184 Pages
Delivery time: 3-5 business days
Price
Back to Top
Global Peptide Cancer Vaccine Market Research Report 2018
Published: December 5, 2018 Content info: 184 Pages
Description

This report studies the Peptide Cancer Vaccine market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Peptide Cancer Vaccine market by product type and applications/end industries.

The major players in global Peptide Cancer Vaccine market include

TapImmune

BrightPath Biotherapeutics

Ultimovacs

Sellas

Boston Biomedical

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Immatics

Geographically, this report is segmented into several key Regions, with market size, market share and growth rate of Peptide Cancer Vaccine in these regions, from 2020 to 2030 (forecast), covering

USA

Europe

China

Japan

South America

RoW

On the basis on the end users/applications, this report covers

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Table of Contents

Table of Contents

1 Peptide Cancer Vaccine Market Overview 1

  • 1.1 Peptide Cancer Vaccine Product Overview 1
  • 1.2 Peptide Vaccine Strategies in the Treatment of Cancer 1
  • 1.3 Global Peptide Cancer Vaccine Segment by Applications 4
    • 1.3.1 Global Peptide Cancer Vaccine Revenue Market Share by Applications in 2025 4
    • 1.3.2 Breast Cancer 4
    • 1.3.3 Lung Cancer 5
    • 1.3.4 Melanoma 6
    • 1.3.5 Prostate Cancer 7
  • 1.4 Global Peptide Cancer Vaccine Market by Regions (2020-2030) 8
    • 1.4.1 Global Peptide Cancer Vaccine Market Size and Growth Rate Comparison by Regions (2020-2030) 8
    • 1.4.2 USA Peptide Cancer Vaccine Status and Prospect (2020-2030) 9
    • 1.4.3 Europe Peptide Cancer Vaccine Status and Prospect (2020-2030) 10
    • 1.4.4 Japan Peptide Cancer Vaccine Status and Prospect (2020-2030) 11
    • 1.4.5 China Peptide Cancer Vaccine Status and Prospect (2020-2030) 12
    • 1.4.6 South America Peptide Cancer Vaccine Status and Prospect (2020-2030) 13
  • 1.5 Global Peptide Cancer Vaccine Market Size (2020-2030) 14
  • 1.6 Global Manufacturers Peptide Cancer Vaccine Headquarters, Established Date and Product 14

2 Cancer Vaccines and Immunotherapy 16

  • 2.1 Therapeutic Vaccines 16
    • 2.1.1 Autologous Cancer Vaccines 17
    • 2.1.2 Allogenic Cancer Vaccines 18
    • 2.1.3 Protein or Peptide Cancer Vaccines 18
    • 2.1.4 DNA Vaccines 18
  • 2.2 Other Approaches 18
  • 2.3 Clinical Considerations for Therapeutic Cancer Vaccines 19
    • 2.3.1 Considerations for both Early and Late Phase Clinical Trials 20
    • 2.3.2 Considerations for Early Phase Clinical Trials 20
    • 2.3.3 Considerations for Late Phase Clinical Trials 21

3 Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer 22

  • 3.1 Peptides & Colorectal Cancer 22
    • 3.1.1 Colorectal Cancer Introduction 22
    • 3.1.2 Introduction of the Number of Patients with Colorectal Cancer 22
    • 3.1.3 Peptide Cancer Vaccine Introduction about Colorectal Cancer 23
  • 3.2 Peptides & Lung Cancer 24
    • 3.2.1 Lung Cancer Introduction 24
    • 3.2.2 Introduction of the Number of Patients with Lung Cancer 25
    • 3.2.3 Peptide Cancer Vaccine Introduction about Lung Cancer 27
  • 3.3 Peptides & Pancreatic Cancer 28
    • 3.3.1 Pancreatic Cancer Introduction 28
    • 3.3.2 Introduction of the Number of Patients with Pancreatic Cancer 29
    • 3.3.3 Peptide Cancer Vaccine Introduction about Pancreatic Cancer 30
  • 3.4 Peptides & Breast Cancer 31
    • 3.4.1 Breast Cancer Introduction 31
    • 3.4.2 Introduction of the Number of Patients with Breast Cancer 31
    • 3.4.3 Peptide Cancer Vaccine Introduction about Breast Cancer 32
  • 3.5 Peptides & Prostate Cancer 33
    • 3.5.1 Prostate Cancer Introduction 33
    • 3.5.2 Introduction of the Number of Patients with Prostate Cancer 34
    • 3.5.3 Peptide Cancer Vaccine Introduction about Prostate Cancer 35
  • 3.6 Peptides & Other Cancer 36

4 Global Peptide Cancer Vaccine by Pipeline 39

  • 4.1 ITK-1 39
  • 4.2 GRN-1201 40
  • 4.3 TPIV200 42
  • 4.4 TPIV110 42
  • 4.5 UV1 43
  • 4.6 galinpepimut-S 44
  • 4.7 TARP 27-35 44
  • 4.8 HER-Vaxx 45
  • 4.9 Vx-001 47
  • 4.10 Vx-006 48
  • 4.11 Vx-016 48
  • 4.12 AE37 49
  • 4.13 ISA101 (HPV) 51
  • 4.14 MyISA (Personalized immunotherapy based on neoantigens) 52
  • 4.15 ISA203 (PRAME) 53
  • 4.16 ISA204 (HBV) 53
  • 4.17 OTSA101 54
  • 4.18 GALINPEPIMUT-S AND KEYTRUDA (PEMBROLIZUMAB) 55
  • 4.19 ACTolog 56
  • 4.20 DSP-7888 Dosing Emulsion plus Bevacizumab 57
  • 4.21 DSP-7888 in Patients with Myelodysplastic Syndrome (MDS) 57
  • 4.22 DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas 58
  • 4.23 DSP-7888 Dosing Emulsion in Adult Patients with Advanced Malignancies 58

5 Global Cancer Vaccine Consumption by Regions (2013-2018) 59

  • 5.1 Global Cancer Vaccine Consumption by Regions (2013-2018) 59
  • 5.2 North America Cancer Vaccine Consumption (2013-2018) 63
  • 5.3 Europe Cancer Vaccine Consumption (2013-2018) 65
  • 5.4 China Cancer Vaccine Consumption (2013-2018) 67
  • 5.5 Japan Cancer Vaccine Consumption (2013-2018) 69

6 Cancer Vaccine Market Size Analysis by Main Players 2013-2018 71

  • 6.1 Global Cancer Vaccine Sales and Share by Manufacturers (2013-2018) 71
  • 6.2 Global Cancer Vaccine Revenue and Share by Manufacturers (2013-2018) 73
  • 6.3 Vaccine Market Size Analysis by Main Players 74
    • 6.3.1 Merck 74
    • 6.3.2 GSK 79
    • 6.3.3 Dendreon 82

7 Analysis of Peptide Cancer Vaccine Industry Key Manufacturers 86

  • 7.1 Boston Biomedical 86
    • 7.1.1 Company Profile 86
    • 7.1.2 Product Information 87
  • 7.2 Ultimovacs 87
    • 7.2.1 Company Profile 87
    • 7.2.2 Product Information 88
  • 7.3 BrightPath Biotherapeutics 90
    • 7.3.1 Company Profile 90
    • 7.3.2 Product Information 92
  • 7.4 TapImmune 94
    • 7.4.1 Company Profile 94
    • 7.4.2 Product Information 96
  • 7.5 Immatics 97
    • 7.5.1 Company Profile 97
    • 7.5.2 Product Information 98
  • 7.6 Sellas 99
    • 7.6.1 Company Profile 99
    • 7.6.2 Product Information 100
  • 7.7 Imugene 101
    • 7.7.1 Company Profile 101
    • 7.7.2 Product Information 102
  • 7.8 VAXON Biotech 102
    • 7.8.1 Company Profile 102
    • 7.8.2 Product Information 104
  • 7.9 Generex Biotechnology 104
    • 7.9.1 Company Profile 104
    • 7.9.2 Product Information 106
  • 7.10 ISA Pharmaceuticals 106
    • 7.10.1 Company Profile 106
    • 7.10.2 Product Information 107
  • 7.11 OncoTherapy Science 108
    • 7.11.1 Company Profile 108
    • 7.11.2 Product Information 110

8 Peptide Cancer Vaccine Manufacturing Cost Analysis 112

  • 8.1 Peptide Cancer Vaccine R&D Cost Analysis 112
    • 8.1.1 Clinical Phase Costs 113
    • 8.1.2 Capitalized Costs 114
  • 8.2 Proportion of Manufacturing Cost Structure 115
    • 8.2.1 Raw Materials 115
    • 8.2.2 Labor Cost 116
    • 8.2.3 Other Costs Analysis 122
  • 8.3 Manufacturing Process Analysis of Peptide Cancer Vaccine 127

9 Industrial Chain, Sourcing Strategy and Downstream Buyers 130

  • 9.1 Peptide Cancer Vaccine Peptide Cancer Vaccine Discovery and Development Analysis 130
  • 9.2 Upstream Raw Materials Sourcing 131
  • 9.3 Downstream Buyers 132

10 Marketing Strategy Analysis 134

  • 10.1 Marketing Channel 134
    • 10.1.1 Direct Marketing 134
    • 10.1.2 Indirect Marketing 134
    • 10.1.3 Marketing Channel Development Trend 134
  • 10.2 Market Positioning 135
    • 10.2.1 Pricing Strategy 135
    • 10.2.2 Brand Strategy 137

11 Market Effect Factors Analysis 139

  • 11.1 Technology Progress in Related Industry 139
  • 11.2 Consumer Needs/Customer Preference Change 140
  • 11.3 Economic/Political Environmental Change 141

12 Global Peptide Cancer Vaccine Market Forecast (2020-2030) 151

  • 12.1 Global Peptide Cancer Vaccine Revenue Forecast (2020-2030) 151
  • 12.2 Global Peptide Cancer Vaccine Revenue Forecast by Regions (2020-2030) 151
  • 12.3 Global Peptide Cancer Vaccine Consumption Forecast by Regions (2020-2030) 154
    • 12.3.1 USA Peptide Cancer Vaccine Consumption Forecast (2020-2030) 157
    • 12.3.2 Europe Peptide Cancer Vaccine Consumption Forecast (2020-2030) 158
    • 12.3.3 China Peptide Cancer Vaccine Consumption Forecast (2020-2030) 159
    • 12.3.4 Japan Peptide Cancer Vaccine Consumption Forecast (2020-2030) 160
    • 12.3.5 South America Peptide Cancer Vaccine Consumption Forecast (2020-2030) 161
  • 12.4 Global Peptide Cancer Vaccine Consumption Forecast by Application (2020-2030) 161

13 Research Findings and Conclusion 164

14 Methodology and Data Source 165

  • 14.1 Methodology/Research Approach 165
    • 14.1.1 Research Programs/Design 165
    • 14.1.2 Market Size Estimation 166
    • 14.1.3 Market Breakdown and Data Triangulation 167
  • 14.2 Data Source 168
    • 14.2.1 Secondary Sources 168
    • 14.2.2 Primary Sources 169
  • 14.3 Disclaimer 170
  • 14.4 Author List 172

List of Tables and Figures

  • Figure Product Picture of Peptide Cancer Vaccine 1
  • Figure Global Peptide Cancer Vaccine Revenue Market Share by Applications in 2025 4
  • Figure Breast Cancer Examples 5
  • Figure Lung Cancer Examples 6
  • Figure Melanoma Examples 7
  • Figure Prostate Cancer Examples 7
  • Table Peptide Cancer Vaccine Market Size (M USD) Comparison by Regions (2020-2030) 8
  • Figure USA Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 9
  • Figure Europe Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 10
  • Figure Japan Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 11
  • Figure China Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 12
  • Figure South America Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 13
  • Figure Global Peptide Cancer Vaccine Revenue (M USD) Status and Outlook (2020-2030) 14
  • Table Global Players/Manufacturers Peptide Cancer Vaccine Headquarters and Established Date 14
  • Table Global Manufacturers Peptide Cancer Vaccine Product 15

Top 20 Countries Highest Incidence of Colorectal Cancer in 2016 23

Top 20 Countries Highest Incidence of Lung Cancer in 2016 25

  • Figure Percent of New Cases by Age Group: Lung Cancer 26
  • Figure Percent of Deaths by Age Group: Lung Cancer 26
  • Table Active Immunotherapies in Phase III Development 27

Top 20 Countries Highest Incidence of Pancreatic Cancer in 2016 29

  • Table Active Immunotherapies in Phase III Development 30

Top 20 Countries Highest Incidence of Breast Cancer in 2016 32

  • Table Active Immunotherapies in Phase III Development 33
  • Figure Percent of New Cases by Age Group: Prostate Cancer 34
  • Figure Percent of Deaths by Age Group: Prostate Cancer 35
  • Figure Estimated Prostate Cancer Incidence Worldwide in 2016 35

Information about World Cancer Statistics for the Most Common Cancers (excluding non-melanoma Skin Cancer) in 2016 37

  • Table Active Immunotherapies in Phase III Development 37
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 39
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 40
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 41
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 41
  • Figure UV1 Technology 43
  • Figure How HER-Vaxx is Tntended to Work 47
  • Figure Molecular Modeling Study-MHC Class II Receptor 50
  • Figure Li Suppression 50
  • Figure Li-KEY Hybrid 51
  • Figure Antitumor Activity of OTSA101 55
  • Figure Peptide Cancer Vaccine Product Information of Sellas 55
  • Figure Peptide Cancer Vaccine Product Information of Immatics 56
  • Figure Peptide Cancer Vaccine Product Information of Boston Biomedical 57
  • Figure Peptide Cancer Vaccine Product Information of Sumitomo Dainippon 57
  • Figure Peptide Cancer Vaccine Product Information of Sumitomo Dainippon 58
  • Figure Peptide Cancer Vaccine Product Information of Boston Biomedical 58
  • Table Global Cancer Vaccine Consumption (K Doses) Market by Regions (2013-2018) 59
  • Table Global Cancer Vaccine Consumption Market Share by Regions (2013-2018) 59
  • Figure Global Cancer Vaccine Consumption Market Share by Regions (2013-2018) 60
  • Figure 2017 Global Cancer Vaccine Consumption Market Share by Regions 60
  • Table Global Cancer Vaccine Revenue (M USD) Market by Regions (2013-2018) 61
  • Table Global Cancer Vaccine Revenue Market Share by Regions (2013-2018) 61
  • Figure Global Cancer Vaccine Revenue Market Share by Regions (2013-2018) 61
  • Figure 2017 Global Cancer Vaccine Revenue Market Share by Regions 62
  • Figure North America Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 63
  • Figure North America Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 64
  • Figure Europe Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 65
  • Figure Europe Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 66
  • Figure China Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 67
  • Figure China Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 68
  • Figure Japan Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 69
  • Figure Japan Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 70
  • Table Global Cancer Vaccine Sales (K Doses) of Key Manufacturers (2013-2018) 71
  • Table Global Cancer Vaccine Sales Market Share by Manufacturers (2013-2018) 71
  • Figure 2013 Cancer Vaccine Sales Market Share by Manufacturers 72
  • Figure 2017 Cancer Vaccine Sales Market Share by Manufacturers 72
  • Table Global Cancer Vaccine Revenue (M USD) by Manufacturers (2013-2018) 73
  • Table Global Cancer Vaccine Revenue Share by Manufacturers (2013-2018) 73
  • Figure 2013 Global Cancer Vaccine Revenue Share by Manufacturers 73
  • Figure 2017 Global Cancer Vaccine Revenue Share by Manufacturers 74
  • Table Merck Company Profile 74
  • Table Cancer Vaccine Product Information of Merck 76
  • Table Cancer Vaccine Sales (K Doses), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of Merck 2013-2018 77
  • Figure Cancer Vaccine Sales (K Doses) and Growth Rate of Merck 2013-2018 78
  • Figure Cancer Vaccine Revenue (M USD) and Global Market Share of Merck 2013-2018 79
  • Table GSK Company Profile 79
  • Table Cancer Vaccine Product Information of GSK 80
  • Table Cancer Vaccine Sales (K Doses), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of GSK 2013-2018 81
  • Figure Cancer Vaccine Sales (K Doses) and Growth Rate of GSK 2013-2018 81
  • Figure Cancer Vaccine Revenue (M USD) and Global Market Share of GSK 2013-2018 82
  • Table Dendreon Company Profile 82
  • Table Cancer Vaccine Product Information of Dendreon 83
  • Table Cancer Vaccine Sales (K Doses), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of Dendreon 2013-2018 84
  • Figure Cancer Vaccine Sales (K Doses) and Growth Rate of Dendreon 2013-2018 84
  • Figure Cancer Vaccine Revenue (M USD) and Global Market Share of Dendreon 2013-2018 85
  • Table Boston Biomedical Company Profile 86
  • Figure Peptide Cancer Vaccine Product Information of Boston Biomedical 87
  • Table Ultimovacs Company Profile 87
  • Table Peptide Cancer Vaccine Product Picture and Specifications of Ultimovacs 88
  • Table BrightPath Biotherapeutics Company Profile 90
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 92
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 93
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 94
  • Table TapImmune Company Profile 94
  • Figure Peptide Cancer Vaccine Product Picture and Specifications of TapImmune 96
  • Table Immatics Company Profile 97
  • Figure Peptide Cancer Vaccine Product Information of Immatics 98
  • Table Sellas Company Profile 99
  • Figure Peptide Cancer Vaccine Product Information of Sellas 100
  • Table Imugene Company Profile 101
  • Figure Peptide Cancer Vaccine Product Picture of Imugene 102
  • Table VAXON Biotech Company Profile 102
  • Figure Peptide Cancer Vaccine Product Picture of VAXON Biotech 104
  • Table Generex Biotechnology Company Profile 104
  • Figure Peptide Cancer Vaccine Product Picture of Generex Biotechnology 106
  • Table ISA Pharmaceuticals Company Profile 106
  • Table OncoTherapy Science Company Profile 108
  • Figure Peptide Cancer Vaccine Product Picture of OncoTherapy Science 110
  • Figure Typical Phases from Research to the Market for a Cancer Vaccine Candidate 113
  • Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 114
  • Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 115
  • Figure Manufacturing Cost Structure of Peptide Cancer Vaccine 115
  • Figure USA Overview of Average Hourly Wages 2015-2016 (USD/Hour) 116
  • Figure USA Overview of Labor Costs 2013-2016 (110 Index Points) 117
  • Figure Cost of Employing a Factory Worker 118
  • Figure 2016 Estimated Labor Costs for the Whole Economy in Europe 119
  • Figure Monthly Minimum Wages in Asia 2016 120
  • Figure China Overview of Average Yearly Wages 2016-2017 (CNY/Year) 121
  • Figure Japan Overview of Average Monthly Wages 2016-2017 (JPY Thousand/Month) 121
  • Table Average Price of Electricity to Ultimate Customers 122
  • Figure Electricity Prices for Household Consumers in 2016 123
  • Figure Summary of the Driving Assumptions 124
  • Figure Industrial Electric Rates 2016 (PER KWH) 125
  • Figure Anti-cancer Process 127
  • Figure Manufacturing Process Analysis of Peptide Cancer Vaccine 128
  • Figure Roadmap to the Development of Predictive Biomarkers for Active Immunotherapy 129
  • Figure Peptide Cancer Vaccine Discovery and Development 130
  • Table Major Buyers of Peptide Cancer Vaccine 132
  • Figure Setting Pricing Policy 136
  • Figure Global GDP Growth Rate for 2016 142
  • Figure Real GDP Growth 2016-2020 annual Average 143
  • Figure US GDP 2006-2016 (Billion USD) 144
  • Figure US CPI Change 2016-2017 144
  • Figure EU GDP 2006-2016 (Billion USD) 145
  • Figure EU CPI Change 2012-2016 145
  • Figure Germany GDP 2006-2016 (Billion USD) 146
  • Figure Germany CPI Change 2016-2017 146
  • Figure UK GDP 2006-2016 (Billion USD) 147
  • Figure UK CPI Change 2016-2017 147
  • Figure Italy GDP 2006-2016 (Billion USD) 148
  • Figure Italy CPI Change 2016-2017 148
  • Figure Japan GDP 2006-2016 (Billion USD) 149
  • Figure Japan CPI Change 2012-2016 149
  • Figure China GDP 2006-2016 (Billion USD) 150
  • Figure China CPI Change 2016-2017 150
  • Figure Global Peptide Cancer Vaccine Revenue (M USD) and Growth Rate Forecast (2020-2030) 151
  • Table Global Peptide Cancer Vaccine Revenue (M USD) Forecast by Regions (2020-2025) 151
  • Table Global Peptide Cancer Vaccine Revenue (M USD) Forecast by Regions (2025-2030) 152
  • Table Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2020-2025) 152
  • Table Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2025-2030) 152
  • Figure Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2020-2030) 153
  • Figure Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions in 2025 153
  • Table Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Regions (2020-2025) 154
  • Table Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Regions (2025-2030) 154
  • Table Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions (2020-2025) 154
  • Table Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions (2025-2030) 155
  • Figure Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions (2020-2030) 155
  • Figure Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions in 2025 156
  • Figure USA Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 157
  • Figure Europe Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 158
  • Figure China Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 159
  • Figure Japan Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 160
  • Figure South America Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 161
  • Table Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Application (2020-2025) 161
  • Table Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Application (2025-2030) 162
  • Table Global Peptide Cancer Vaccine Consumption Forecast by Application (2020-2025) 162
  • Table Global Peptide Cancer Vaccine Consumption Forecast by Application (2025-2030) 162
  • Figure Global Peptide Cancer Vaccine Consumption Forecast by Application (2020-2030) 163
  • Figure Global Peptide Cancer Vaccine Consumption Forecast by Application in 2025 163
  • Table Research Programs/Design for This Report 165
  • Figure Bottom-up and Top-down Approaches for This Report 167
  • Figure Data Triangulation 168
  • Table Key Data Information from Secondary Sources 169
  • Table Key Data Information from Primary Sources 170
Back to Top